Description
Latin name
ACP
Release form
Eisipi film-coated tablets.
Packing
7 pcs – blister packagings (4) – packs of cardboard.
Indications
Depression, panic disorder (including with agoraphobia).
Contraindications
Concomitant use of MAO inhibitors, children and adolescents under 15 years of age, pregnancy, lactation, hypersensitivity to escitalopram.
Caution should be used for cirrhosis, renal failure (CC less than 30 ml / min), advanced age.
Pregnancy and lactation
Pregnancy and lactation (breastfeeding) are contraindicated.
Composition
1 tablet contains
Active ingredient:
escitalopram – 10 mg.
Dosage and administration
Take orally, regardless of food intake.
Depending on the indications, a single dose is 10-20 mg / day. The maximum daily dose is 20 mg. The duration of treatment is several months. Upon termination of treatment, the dose should gradually decrease over 1-2 weeks. in order to avoid the occurrence of withdrawal syndrome.
For elderly patients (over 65), the recommended dose is 5 mg / day, the maximum daily dose is 10 mg.
In case of impaired liver function, the recommended initial within the first 2 weeks. treatment is 5 mg / day. Depending on the individual reaction, the dose may be increased to 10 mg / day.
For patients with low activity of the CYP2C19 isoenzyme, the recommended initial dose for the first 2 weeks. treatment – 5 mg / day. Depending on the individual reaction, the dose may be increased to 10 mg / day.
Side effects of
From the central nervous system and peripheral nervous system: dizziness, weakness, insomnia or drowsiness, convulsions, tremors, motor disorders, serotonin syndrome (agitation, tremors, myoclonus, hyperthermia), hallucinations, anxiety, confusion, confusion , depersonalization, panic attacks, increased irritability, visual disturbances.
From the digestive system: nausea, vomiting, dry mucous membranes of the oral cavity, taste disturbances, decreased appetite, diarrhea, constipation, and changes in laboratory parameters of liver function.
From the cardiovascular system: orthostatic hypotension.
From the endocrine system: decreased secretion of ADH, galactorrhea.
From the reproductive system: decreased libido, impotence, impaired ejaculation, anorgasmia (in women).
From the urinary system: urinary retention.
Dermatological reactions: skin rash, itching, ecchymosis, purpura, increased sweating.
Allergic reactions: angioedema, anaphylactic reactions.
From the side of metabolism: hyponatremia, hyperthermia.
From the musculoskeletal system: arthralgia, myalgia.
Other: sinusitis, withdrawal syndrome (dizziness, headaches, and nausea).
Drug Interaction
When used concurrently with MAO inhibitors increases the risk of serotonin syndrome and serious adverse reactions.
Co-administration with serotonergic agents (including tramadol, triptans) can lead to the development of serotonin syndrome.
When used concurrently with drugs that reduce the seizure threshold, increases the risk of seizures.
Escitalopram enhances the effects of tryptophan and lithium drugs, increases the toxicity of St. John’s wort drugs, the effects of drugs, influencing blood coagulation (control of blood coagulation indicators is required).
Drugs metabolized with the participation of the CYP2C19 isoenzyme (including omeprazole), as well as being potent inhibitors of CYPZA4 and CYP2D6 (including flecainide, propafenone, metoprolol, desipramine, clomipriperin, nortperidol, riparisperidol increase the concentration of escitalopram in blood plasma.
Escitalopram increases plasma concentrations of desipramine and metoprolol 2-fold.
Storage conditions
At a temperature not exceeding 25 ° C. Keep out of the reach of children.
Shelf life
2 years.
Active ingredient
Escitalopram
tablet dosage form of tablets
Possible Product Name
Eisipi tablets coated. 10 mg 28 pcs.
